Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Sitagliptin
Drug: LCQ908A
Drug: Placebo
Drug: metformin

First Posted Date: 2009-05-14

Last Posted Date: 2013-01-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 693

Registration Number: NCT00901979

Locations: 🇺🇸
Metabolic Research Institute, Inc., West Palm Beach, Florida, United States
🇺🇸
John Muir Clinical Research, Concord, California, United States
🇺🇸
Dallas Diabetic and Endocrinology Research Center, Dallas, Texas, United States

and more 64 locations

Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase 2

Completed

Conditions: Diabetic Macular Edema
Visual Impairment

Interventions: Drug: RFB002
Procedure: Laser photocoagulation

First Posted Date: 2009-05-13

Last Posted Date: 2017-03-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 83

Registration Number: NCT00901186

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol 150 μg
Drug: Tiotropium 18 μg
Drug: Placebo to tiotropium
Drug: Placebo to indacaterol

First Posted Date: 2009-05-13

Last Posted Date: 2011-08-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1598

Registration Number: NCT00900731

Locations: 🇨🇦
Novartis Investigative SIte, Quebec, Canada
🇬🇧
Novartis Investigator Site, Watford, United Kingdom
🇹🇷
Novartis Investigative Site, Yenisehir/Izmir, Turkey

and more 1 locations

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

Phase 3

Completed

Conditions: Acute Decompensated Heart Failure
Congestive Heart Failure

Interventions: Drug: Placebo
Drug: Aliskiren

First Posted Date: 2009-05-07

Last Posted Date: 2013-11-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1639

Registration Number: NCT00894387

Locations: 🇹🇷
Novartis Investigative Site, Talas / Kayseri, Turkey

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Phase 4

Completed

Conditions: Congestive Heart Failure
Type II Diabetes Mellitus

Interventions: Drug: placebo of vildagliptin
Drug: vildagliptin

First Posted Date: 2009-05-07

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 798

Registration Number: NCT00894868

Locations: 🇸🇰
Novartis Investigative Site, Modava Nad Bodvou, Slovakia

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

Phase 3

Completed

Conditions: Systemic Juvenile Idiopathic Arthritis

Interventions: Drug: Canakinumab

First Posted Date: 2009-04-30

Last Posted Date: 2019-03-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 270

Registration Number: NCT00891046

Locations: 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Phase 3

Completed

Conditions: Systemic Juvenile Idiopathic Arthritis With Active Flare

Interventions: Drug: placebo
Drug: canakinumab

First Posted Date: 2009-04-29

Last Posted Date: 2012-10-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 177

Registration Number: NCT00889863

Locations: 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇹🇷
Novartis Investigative Site, Izmir, Turkey

and more 11 locations

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

Phase 2

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: LCZ696
Drug: Valsartan
Drug: Placebo

First Posted Date: 2009-04-24

Last Posted Date: 2015-08-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 307

Registration Number: NCT00887588

Locations: 🇻🇪
Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

Phase 3

Terminated

Conditions: Systemic Juvenile Idiopathic Arthritis

Interventions: Drug: Canakinumab
Drug: Placebo

First Posted Date: 2009-04-23

Last Posted Date: 2017-03-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 84

Registration Number: NCT00886769

Locations: 🇺🇸
St. Barnabas Ambulatory Care Center, Livingston, New Jersey, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Arkansas Children's Hospital Research Inst, Little Rock, Arkansas, United States

and more 14 locations

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

Phase 2

Completed

Conditions: Moderate and Severe Plaque Psoriasis

Interventions: Drug: AEB071
Drug: Placebo

First Posted Date: 2009-04-21

Last Posted Date: 2020-12-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 336

Registration Number: NCT00885196

Locations: 🇺🇸
Kansas City Dermatology, PA, Overland Park, Kansas, United States
🇺🇸
Palmetto Clinical Trial Services, Greenville, South Carolina, United States
🇹🇷
Novartis Investigative Site, Manisa, Turkey

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy